Charles Rudin, MD on KEYNOTE-604: Pembrolizumab or Placebo Plus Etoposide as Therapy in SCLC #ASCO2020 @charlesrudin #ASCO @sloan_kettering

Charles Rudin, MD on KEYNOTE-604: Pembrolizumab or Placebo Plus Etoposide as Therapy in SCLC #ASCO2020 @charlesrudin #ASCO @sloan_kettering

User Photo
Cancer-News

4 months
349 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Charles Rudin, MD @charlesrudin of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses KEYNOTE-604: pembrolizumab versus placebo plus etoposide and platnium as a first-line therapy in SCLC.

Up Next Autoplay
>